Bullfrog ai launches preclinical study to investigate bf-114's potential in battling obesity

The market for obesity drugs is projected to exceed $77 billion by 2030 dr. randy seeley, a recognized expert on novel treatments for obesity, to lead study gaithersburg, md., dec. 06, 2023 (globe newswire) -- bullfrog ai holdings, inc. (nasdaq: bfrg; bfrgw) ("bullfrog ai" or the "company"), a technology-enabled drug development company using artificial intelligence (ai) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the launch of a preclinical study to evaluate the efficacy of its drug candidate bf-114 in obesity.
BFRG Ratings Summary
BFRG Quant Ranking